Skip to main content
SpringerLink
Log in

Nivolumab ist eine neue Therapieoption beim metastasierten Nierenzellkarzinom

Ergebnisse der Phase-III-Studie CheckMate 025

Nivolumab is a new therapy option for metastasized renal cell carcinoma

Results of the phase III study CheckMate 025

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813

    Article  CAS  PubMed  Google Scholar 

  2. Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814–1823

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):917–927

    Article  CAS  PubMed  Google Scholar 

  4. Powles T, Staehler M, Ljungberg B et al (2016) Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy. Eur Urol 69:4–6

    Article  PubMed  Google Scholar 

  5. George S, Robert J, Motzer RJ, Hammers HJ et al (2016) Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2(9):1179–1186

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1‑3, 68167, Mannheim, Deutschland

    Philipp Nuhn

  2. Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, Ulm, Deutschland

    Christian Bolenz

Authors
  1. Philipp Nuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Bolenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Nuhn.

Ethics declarations

Interessenkonflikt

P. Nuhn und C. Bolenz geben an, dass kein Interessenskonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nuhn, P., Bolenz, C. Nivolumab ist eine neue Therapieoption beim metastasierten Nierenzellkarzinom. Onkologe 23, 232–233 (2017). https://doi.org/10.1007/s00761-017-0191-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-017-0191-0

Search

Navigation